Hefei Lifeon Pharmaceutical Secures Regulatory Approval for Dexmethylphenidate Hydrochloride API
Stock News
Sep 21
Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) has announced that it recently received the "Chemical API Marketing Authorization Approval Notice" issued by China's National Medical Products Administration for its dexmethylphenidate hydrochloride active pharmaceutical ingredient.
Dexmethylphenidate hydrochloride is a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD).
The receipt of this approval marks a significant regulatory milestone for the company's product pipeline, allowing it to proceed with the commercial production and marketing of this API in the domestic market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.